FILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera/File Photo
(Reuters) – GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million).
The sale of anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, by the British drugmaker includes milestone payments of up to 495 million euros.
Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Arun Koyyur
Our Standards:The Thomson Reuters Trust Principles.
